DE60313005D1 - Behandlung von dyskinesie mit 2,3-benzodiazepinen - Google Patents

Behandlung von dyskinesie mit 2,3-benzodiazepinen

Info

Publication number
DE60313005D1
DE60313005D1 DE60313005T DE60313005T DE60313005D1 DE 60313005 D1 DE60313005 D1 DE 60313005D1 DE 60313005 T DE60313005 T DE 60313005T DE 60313005 T DE60313005 T DE 60313005T DE 60313005 D1 DE60313005 D1 DE 60313005D1
Authority
DE
Germany
Prior art keywords
dyskinesia
benzodiazepines
treatment
pakinsonism
nerisopam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60313005T
Other languages
English (en)
Other versions
DE60313005T2 (de
Inventor
Alan Crossman
Michael Hill
Jonathan Brotchie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Motac Neuroscience Ltd
Original Assignee
Motac Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0221248A external-priority patent/GB0221248D0/en
Priority claimed from GB0304227A external-priority patent/GB0304227D0/en
Application filed by Motac Neuroscience Ltd filed Critical Motac Neuroscience Ltd
Publication of DE60313005D1 publication Critical patent/DE60313005D1/de
Application granted granted Critical
Publication of DE60313005T2 publication Critical patent/DE60313005T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60313005T 2002-09-13 2003-09-11 Behandlung von dyskinesie mit 2,3-benzodiazepinen Expired - Lifetime DE60313005T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0221248 2002-09-13
GB0221248A GB0221248D0 (en) 2002-09-13 2002-09-13 Treatment of basal ganglia-related movement disorders
GB0304227A GB0304227D0 (en) 2003-02-25 2003-02-25 Treatment of basal ganglia-related movement disorders
GB0304227 2003-02-25
PCT/GB2003/003951 WO2004024163A1 (en) 2002-09-13 2003-09-11 Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines

Publications (2)

Publication Number Publication Date
DE60313005D1 true DE60313005D1 (de) 2007-05-16
DE60313005T2 DE60313005T2 (de) 2007-12-20

Family

ID=31995700

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60313005T Expired - Lifetime DE60313005T2 (de) 2002-09-13 2003-09-11 Behandlung von dyskinesie mit 2,3-benzodiazepinen

Country Status (13)

Country Link
US (1) US20050261282A1 (de)
EP (1) EP1545546B1 (de)
JP (1) JP4630665B2 (de)
CN (1) CN1681512B (de)
AT (1) ATE358488T1 (de)
AU (1) AU2003263357B2 (de)
CA (1) CA2498735C (de)
CY (1) CY1106689T1 (de)
DE (1) DE60313005T2 (de)
DK (1) DK1545546T3 (de)
ES (1) ES2285245T3 (de)
PT (1) PT1545546E (de)
WO (1) WO2004024163A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
CN102836162A (zh) * 2012-04-10 2012-12-26 珠海亿邦制药股份有限公司 一种以托非索泮为活性成分的口服固体制剂及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU179018B (en) * 1978-10-19 1982-08-28 Gyogyszerkutato Intezet Process for producing new 5h-2,3-benzodiazepine derivatives
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4582916A (en) * 1983-09-26 1986-04-15 Mcneilab, Inc. Chlorosulfate and azidosulfate esters of tetrahydro-2H-pyran-2-yl-methanol
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
DE19604920A1 (de) * 1996-02-01 1997-08-07 Schering Ag Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
HUP9701284A3 (en) * 1997-07-24 2005-11-28 Egyt Gyogyszervegyeszeti Gyar Use of 2,3-benzodiazepine derivatives for producing pharmaceutical compositions for treating and prophylacting illnesses and conditions connected with the endogene opioide system
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6583172B1 (en) * 1999-04-08 2003-06-24 Richard P. Shank Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
FR2824065A1 (fr) * 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
US6649607B2 (en) * 2001-05-18 2003-11-18 Vela Pharmaceuticals, Inc. Compositions and methods for treating or preventing convulsions or seizures
RU2195284C1 (ru) * 2001-07-23 2002-12-27 Сибирский государственный медицинский университет Способ лечения гипертонически-гиперкинетической формы дискинезии желчевыводящих путей у лиц молодого возраста
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate

Also Published As

Publication number Publication date
DE60313005T2 (de) 2007-12-20
DK1545546T3 (da) 2007-08-06
WO2004024163A1 (en) 2004-03-25
JP2006502174A (ja) 2006-01-19
US20050261282A1 (en) 2005-11-24
EP1545546A1 (de) 2005-06-29
PT1545546E (pt) 2007-07-02
ES2285245T3 (es) 2007-11-16
CY1106689T1 (el) 2012-05-23
AU2003263357A1 (en) 2004-04-30
CA2498735A1 (en) 2004-03-25
CA2498735C (en) 2011-08-02
CN1681512B (zh) 2011-11-09
AU2003263357B2 (en) 2009-02-26
CN1681512A (zh) 2005-10-12
ATE358488T1 (de) 2007-04-15
JP4630665B2 (ja) 2011-02-09
EP1545546B1 (de) 2007-04-04

Similar Documents

Publication Publication Date Title
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
BRPI0413449A (pt) compostos de quinoxalina
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
RS20050810A (en) 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
ATE401314T1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
BRPI0411617A (pt) derivados de pirimidina como ligantes de receptores de canabinóides
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
GB0225474D0 (en) Therapeutic agents
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ECSP056057A (es) Compuestos de benzo[1,2,5]tiadiazole
DE60127131D1 (de) Tricyclische imidazopyridine
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
ATE358488T1 (de) Behandlung von dyskinesie mit 2,3-benzodiazepinen
BRPI0415355A (pt) triarilimidazóis
NO20053562L (no) Nye aminobenzofenonforbindelser
MXPA06000700A (es) Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.
PT1212119E (pt) Utilizacao de ciamemazina no tratamento do desmame subito de benzodiazepinas
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
UY26498A1 (es) Pirroles sustituidos
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
EP1436279A4 (de) Chemische verbindungen
ATE412411T1 (de) Pmcol zur behandlung von prostatakrebs

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: CROSSMAN, ALAN, MANCHESTER, GB

Inventor name: HILL, MICHAEL, MANCHESTER, GB

Inventor name: BROTCHIE, JONATHAN, TORONTO, ONTARIO, CA

8364 No opposition during term of opposition